Search
for
Sort by
Research 331–360 of 532
- Image 1_Resident T cell activation leads to human hair follicle immune privilege loss ex vivo, which is prevented by the DHODH inhibitor farudodstat: relevance for alopecia areata.pdf
- Long-Term Efficacy and Safety of Ritlecitinib in Adults and Adolescents with Alopecia Areata: 3-Year Results from the ALLEGRO Phase 2b/3 and ALLEGRO-LT Phase 3 Clinical Studies
- Comprehensive Genomic Profiling of Cutaneous Adnexal Carcinomas: A Genomic Landscape Study
- Advances in Medicalized Hair Loss Solutions: A Review of Current Clinical Practices and Regenerative Medicine-Based Protocols with Focus on Off-Label Injectable Treatments
- Evaluation of Hair Fiber and Sensory Properties following the Application of Conditioners containing Jojoba and Coconut Oils
- Long-Term Efficacy and Complete Scalp Hair Regrowth in Patients With Alopecia Areata Receiving Ritlecitinib 50 mg QD Up to 3 Years in the ALLEGRO Clinical Trial Program
- 186 Mechanistic insights into Ritlecitinib-mediated immunomodulation in Alopecia Areata
- Rationale and Design of a Novel, Phase 3, External and Synthetic Placebo-Controlled Clinical Trial of Ritlecitinib 50 mg and 100 mg for Alopecia Areata
- 63418 JAK3/TEC kinase pathways are active in alopecia areata lesions, and their inhibition with Ritlecitinib prevents αCD3/αCD28+IL-2 induced immune privilege collapse in healthy hair follicles ex vivo
- Updated Integrated Safety Analysis of Ritlecitinib Over 72 Months In Patients With Alopecia Areata From the ALLEGRO Clinical Trial Program
- Timing of Initial Hair Regrowth and Clinical Trial-Defined Response Following Ritlecitinib Treatment in Patients With Alopecia Areata
- Multiomics Analysis of the Response to Ritlecitinib in Alopecia Areata Subtypes and Correlation With Efficacy
- Tissue and metabolic regeneration in the light of stem cells, gut microbiota, microRNAs, and exosomes: a systematic review
- ADRENAL FAILURE: WHEN ANTIPHOSPHOLIPID SYNDROME LEAVES SCARS
- Prediction of Long-term Scalp Hair Regrowth at 24 Months in Patients with Alopecia Areata Receiving Ritlecitinib Treatment in the ALLEGRO Clinical Trial Program
- Multiparametric Ultrasound Assessment of Alopecia Areata Plaque with Atrophy After Serial Corticosteroid Infusion
- 487 Exploring ribosomal RNA modifications and corresponding snoRNAs in human skin cell senescence
- Distribution of SALT Scores with Ritlecitinib Treatment up to 24 months from the ALLEGRO Phase 2b/3 and Long-Term Phase 3 Clinical Studies in Alopecia Areata
- 8273 ACTH-Dependent Cushing's Syndrome due to Metastatic Cervical Cancer: A Case Report
- 8273 ACTH-Dependent Cushing's Syndrome Due To Metastatic Cervical Cancer: A Case Report
- LB922 CyTOF immune profiling uncovers sex- and race-specific differences and cellular biomarkers for biologic response in Hidradenitis suppurativa
- Integrated Safety Analysis of Ritlecitinib, an Oral JAK3/TEC Family Kinase Inhibitor, for the Treatment of Alopecia Areata from the ALLEGRO Clinical Trial Program
- Botulinum Toxin A Delivery via MMP Technique: An Emerging Therapeutic Approach for Frontal Fibrosing Alopecia
- Botulinum toxin A as an alternative treatment for folliculitis decalvans
- CARACTERÍSTICAS CLÍNICAS DO EFLÚVIO TELÓGENO INDUZIDO PELA INFECÇÃO DE COVID-19: REVISÃO INTEGRATIVA
- What we already know about the Post-COVID-19 Syndrome: A narrative review
- P381 Kinetics of Titan cells generation and transcriptome modifications comparing three <i>in vitro</i> protocols
- Cardiac Amyloidosis and Aortic Stenosis: When to Consider it and How to Treat it?
- 1378 Identification of two distinct stem cell clusters, Lrig1-derived and Wnt/CD44-dependent, in corneal epithelium
- The influence of non-esterified fatty acids (NEFA) on the ovarian production of androgens in a context of in vitro fertilisation (IVF) – preliminary results